Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. Connect with us on X, LinkedIn and Facebook.
Company Profile
Industry Classifications
Sector
Biopharmaceutical
Industry
Biotechnology
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
Contact Information
Investor Relations
Corbus Pharmaceuticals
Sean Moran
Chief Financial Officer
ir@corbuspharma.com
LifeSci Advisors, LLC
Bruce Mackle
Managing Director
T: 617.415.7745
bmackle@lifesciadvisors.com
Transfer Agent
Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
T: 800.509.5586
cstmail@continentalstock.com
https://www.continentalstock.com
Company Contact
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
T: 617.963.0100
info@corbuspharma.com